MedTech Intelligence

Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia

The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is ...
Medical Device Network on MSN

Prodeon Medical’s BPH implant gains FDA clearance

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score ...
MassDevice

Prodeon gets FDA clearance for BPH-treating nitinol implant

Image courtesy of Prodeon Medical] Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross ...
Insider Monkey

Profound Medical Completes First Commercial BPH Treatment With New TULSA-AI Volume Reduction Module

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...
Business Wire

MarinHealth Medical Center Surgeons Perform New AI-Powered Aquablation Procedure for the Treatment of Benign Prostatic Hyperplasia

GREENBRAE, Calif.--(BUSINESS WIRE)--MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat benign prostatic hyperplasia (BPH).
Barron's

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO(R) Clinical Data, at RSNA and SUO Meetings

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...